Xtant Medical (NYSEAMERICAN:XTNT) Stock Crosses Above 200 Day Moving Average - Time to Sell?

Key Points

• Xtant Medical's shares have surpassed their 200-day moving average, trading at $0.63 after reaching a high of $0.65 during Thursday's trading session.
• The company has a current market capitalization of $82.10 million, with a PE ratio of -15.75, indicating negative earnings.
• Recent institutional trading saw significant increases in holdings, with Jane Street Group and AWM Investment Company being among the notable investors, bringing institutional ownership to 69.33% of the company’s stock.

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report)'s share price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.57 and traded as high as $0.65. Xtant Medical shares last traded at $0.63, with a volume of 68,143 shares changing hands.

Xtant Medical Trading Up 1.4%

The company has a market capitalization of $83.27 million, a P/E ratio of -15.98 and a beta of -0.15. The business has a fifty day moving average price of $0.63 and a 200 day moving average price of $0.57. The company has a quick ratio of 1.16, a current ratio of 2.47 and a debt-to-equity ratio of 0.46.

Institutional Trading of Xtant Medical

A number of institutional investors have recently modified their holdings of the company. Nantahala Capital Management LLC lifted its holdings in shares of Xtant Medical by 500.3% in the second quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company's stock valued at $50,543,000 after purchasing an additional 57,000,000 shares in the last quarter. AWM Investment Company Inc. bought a new stake in shares of Xtant Medical in the second quarter worth $4,875,000. Renaissance Technologies LLC lifted its position in shares of Xtant Medical by 15.0% in the fourth quarter. Renaissance Technologies LLC now owns 798,033 shares of the medical device company's stock worth $354,000 after purchasing an additional 103,825 shares in the last quarter. Crescent Grove Advisors LLC lifted its position in shares of Xtant Medical by 94.3% in the second quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company's stock worth $304,000 after purchasing an additional 200,000 shares in the last quarter. Finally, Mink Brook Asset Management LLC lifted its position in shares of Xtant Medical by 125.8% in the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company's stock worth $81,000 after purchasing an additional 60,997 shares in the last quarter. 69.33% of the stock is currently owned by institutional investors.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.